Denali Therapeutics Quote - DNLI

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

21.50

Bid

21.40

Ask

22.00

Volume

1,660,734

18.69 Day's Range 21.61

14.56 52 Week Range 33.33

Market Cap

3.094B

Previous Close

19.82

Open

18.75

Last Trade

7794

21.5

(formt)

Last Trade Time

Financial Volume

US$ 34,999,320

VWAP

21.0746

Average Volume (3m)

852,530

Shares Outstanding

143,921,624

Dividend Yield

PE Ratio

-21.01

Earnings Per Share (EPS)

-1.01

Revenue

330.53M

Net Profit

-145.22M

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates ... Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.denalitherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

Denali Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was US$19.82. Over the last year, Denali Therapeutics shares have traded in a share price range of US$ 14.56 to US$ 33.33.

Denali Therapeutics currently has 143,921,624 shares outstanding. The market capitalization of Denali Therapeutics is US$2.85 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -21.01.

Overall Flow

Bearish

Net Premium

-1k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeksOverall, DNL343 was found to be safe...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.09	5.34051935326	20.41	21.58	19.73	862614	20.37480337	CS
4	-3.46	-13.8621794872	24.96	25.48	19.73	976196	21.7240649	CS
12	-5.42	-20.1337295691	26.92	33.33	19.73	852530	24.79178107	CS
26	0.13	0.608329433786	21.37	33.33	19.73	907043	25.18171404	CS
52	2.24	11.6303219107	19.26	33.33	14.56	1039769	21.8553303	CS
156	-21.85	-50.4036908881	43.35	44.2	14.56	827893	24.93889218	CS
260	4.27	24.7823563552	17.23	93.94	12.39	737195	32.02674436	CS

DNLI - Frequently Asked Questions (FAQ)

What is the current Denali Therapeutics share price?

The current share price of Denali Therapeutics is US$ 21.50

How many Denali Therapeutics shares are in issue?

Denali Therapeutics has 143,921,624 shares in issue

What is the market cap of Denali Therapeutics?

The market capitalisation of Denali Therapeutics is USD 2.85B

What is the 1 year trading range for Denali Therapeutics share price?

Denali Therapeutics has traded in the range of US$ 14.56 to US$ 33.33 during the past year

What is the PE ratio of Denali Therapeutics?

The price to earnings ratio of Denali Therapeutics is -21.01

What is the cash to sales ratio of Denali Therapeutics?

The cash to sales ratio of Denali Therapeutics is 9.23

What is the reporting currency for Denali Therapeutics?

Denali Therapeutics reports financial results in USD

What is the latest annual turnover for Denali Therapeutics?

The latest annual turnover of Denali Therapeutics is USD 330.53M

What is the latest annual profit for Denali Therapeutics?

The latest annual profit of Denali Therapeutics is USD -145.22M

What is the registered address of Denali Therapeutics?

The registered address for Denali Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Denali Therapeutics website address?

The website address for Denali Therapeutics is www.denalitherapeutics.com

Which industry sector does Denali Therapeutics operate in?

Denali Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DATSDatChat Inc	US$ 8.82 (350.00%)	204.79M
HOTHHoth Therapeutics Inc	US$ 2.22 (170.86%)	415.2M
DRIODarioHealth Corporation	US$ 1.5479 (81.68%)	2.48M
SVMHSRIVARU Holding Ltd	US$ 0.0829 (79.05%)	1.38B
SPISPI Energy Company Ltd	US$ 0.6755 (57.09%)	136.4M
DHAIDIH Holdings US Inc	US$ 1.7899 (-38.70%)	1.52M
CISOCISO Global Inc	US$ 1.70 (-37.04%)	692.1k
SLRNACELYRIN Inc	US$ 2.21 (-36.68%)	11.57M
BOXLBoxlight Corporation	US$ 1.16 (-30.95%)	6.54M
AMSTAmesite Inc	US$ 2.80 (-30.86%)	943.11k
XTIAXTI Aerospace Inc	US$ 0.1141 (29.66%)	2.64B
SVMHSRIVARU Holding Ltd	US$ 0.0829 (79.05%)	1.38B
CEROCERo Therapeutics Holdings Inc	US$ 0.0515 (21.75%)	900.12M
RIMEAlgorhythm Holdings Inc	US$ 0.22647 (56.40%)	667.47M
HOTHHoth Therapeutics Inc	US$ 2.22 (170.86%)	415.2M